Literature DB >> 2474611

Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies.

J S Kenney1, B W Hughes, M P Masada, A C Allison.   

Abstract

Five adjuvants were compared to Freund's adjuvant for production of mouse polyclonal antibodies and monoclonal antibodies (McAbs) to human serum albumin (HSA) and interleukin-1 alpha (IL-1 alpha). Parameters examined were titer, affinity, concentration, isotype, epitope specificity and neutralizing activity of sera and hybridoma supernatants. Freund's adjuvant, while producing high titers and concentrations of antibodies in sera, was inferior to other adjuvants for eliciting antibodies with particular qualities. The adjuvants Quil A and A1(OH)3/[Thr1]muramyldipeptide elicited the highest affinity antibodies to HSA. Syntex adjuvant formulation-1 (SAF-1) elicited the highest percentage of 'protective' IgG2a antibodies to HSA. All adjuvants, particularly Quil A and Ribi adjuvant system, where superior to Freund's adjuvant in eliciting antibodies which bound native versus denatured HSA. In a comparison of SAF-1 and Freund's adjuvant, SAF-1 was superior to Freund's adjuvant in eliciting polyclonal and hybridoma antibodies which neutralized the biological activity of IL-1 alpha. These results show that adjuvants selectively and independently enhance different qualities of the antibody response. Furthermore, immunization with the appropriate adjuvant can optimize production of McAbs with desired qualities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474611     DOI: 10.1016/0022-1759(89)90156-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  34 in total

1.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

3.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

5.  Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.

Authors:  R L Richards; M Rao; N M Wassef; G M Glenn; S W Rothwell; C R Alving
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Authors:  Rajesh Kumar; Paresh C Ray; Dibyadyuti Datta; Geetha P Bansal; Evelina Angov; Nirbhay Kumar
Journal:  Vaccine       Date:  2015-08-20       Impact factor: 3.641

7.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Authors:  Jessica A Hess; Bin Zhan; Sandra Bonne-Année; Jessica M Deckman; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  Int J Parasitol       Date:  2014-06-05       Impact factor: 3.981

8.  Concentration determination of a recombinant vaccine antigen adsorbed onto an alum adjuvant by chemiluminescent nitrogen detection.

Authors:  John V Amari; Philip Levesque; Zhirui Lian; Trish Lowden; Uditha deAlwis
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

9.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.

Authors:  Michael Chan; Tomoko Hayashi; Crystal S Kuy; Christine S Gray; Christina C N Wu; Maripat Corr; Wolfgang Wrasidlo; Howard B Cottam; Dennis A Carson
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.